2010年6月
New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group
BIOORGANIC & MEDICINAL CHEMISTRY
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 18
- 号
- 11
- 開始ページ
- 3925
- 終了ページ
- 3933
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1016/j.bmc.2010.04.033
- 出版者・発行元
- PERGAMON-ELSEVIER SCIENCE LTD
New 2-aminobenzamide-type histone deacetylase (HDAC) inhibitors were synthesized. They feature a sulfur-containing bicyclic arylmethyl moiety-a surface recognition domain introduced to increase in cellular uptake-and a substituted tert-amino group which affects physicochemical properties such as aqueous solubility. Compound 22 with a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group reduced the volume of human colon cancer HCT116 xenografts in nude mice to T/C 67% by oral administration at 45 mg/kg, which was comparable to the rate (T/C 62%) for a positive control, MS-275. Western blot analyses as well as cell cycle and TUNEL assays by flow cytometry suggested that the two compounds inhibited the growth of cancer cells via similar mechanisms. (C) 2010 Elsevier Ltd. All rights reserved.
- リンク情報
- ID情報
-
- DOI : 10.1016/j.bmc.2010.04.033
- ISSN : 0968-0896
- PubMed ID : 20452226
- Web of Science ID : WOS:000278078600032